A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

被引：0

作者：

Weisel, Katja ^{[1
]}

Hungria, Vania T. M. ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Gabor, Mikala ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Matsumoto, Morio ^{[9
]}

Sule, Neal ^{[10
]}

Li, Mary ^{[10
]}

McKeown, Astrid ^{[11
]}

He, Wei ^{[12
]}

Bright, Shelley ^{[10
]}

Currie, Brooke ^{[13
]}

Boyle, Julia ^{[14
]}

Opalinska, Joanna ^{[10
]}

Dimopoulos, Meletios Athanasios ^{[15
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Dept Hematol, Clin Sao Germano, Sao Paulo, Brazil

[3] Univ Hosp St Ivan Rilski EAD, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Haematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol & Oncol, Porto Alegre, RS, Brazil

[9] Natl Hosp Org, Shibukawa Med Ctr, Shibukawa, Japan

[10] GSK, Upper Providence, PA USA

[11] GSK, Stevenage, Herts, England

[12] GSK, Waltham, MA USA

[13] GSK, Rockville, MD USA

[14] GSK, London, England

[15] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

multiple myeloma; belantamab mafodotin; relapsed/refractory multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-509

引用

页码：S504 / S505

页数：2